IDEXX Laboratories, Inc. (IDXX) Market Cap & Valuation Ratios
IDEXX Laboratories, Inc. (IDXX) has a market cap of $44.1B, a trailing P/E of 39.4 and a price-to-sales ratio of 9.7, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IDXXIDEXX Laboratories, Inc.Follow IDXX — free
—
Price chart with a free account
- Market cap
- 44.1B
- P/E TTM
- 39.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Peers
diagnostics & research · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| IDXX | 44 | 39.4 | 9.9 | 27.9 | 2.8% | +13% | 32% | 49% |
| NTRA | 58 | — | 21.1 | — | 0.1% | +38% | -11% | -51% |
| A | 49 | 34.1 | 6.9 | 26.7 | 2.6% | +9% | 22% | 16% |
| IQV | 46 | 34.7 | 3.5 | 17.7 | 4.7% | +8% | 13% | 9% |
| WAT | 45 | — | 10.6 | 52.1 | 0.9% | +52% | 7% | 2% |
| ILMN | 41 | 50.3 | 9.2 | 36.0 | 2.3% | +5% | 20% | 19% |
| MTD | 33 | 37.6 | 8.6 | 28.4 | 2.6% | +7% | 28% | 49% |
| LH | 27 | 27.2 | 2.3 | 14.8 | 4.3% | +6% | 10% | 9% |
| DGX | 27 | 24.1 | 2.6 | 13.6 | 5.2% | +9% | 15% | 11% |
| GH | 23 | — | 19.6 | — | -1.1% | +43% | -40% | -231% |
| MEDP | 19 | 37.2 | 6.3 | 28.4 | 3.6% | +20% | 21% | — |
| Median of these 10 | 34.7 | 7.8 | 27.6 | 2.6% | +9% | 14% | 9% |
P/E 39.4 vs. a peer median of 34.7; EV/Sales 9.9 vs. 7.8. IDXX's own P/E sits at the 7th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesNTRA and WAT and GH have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
IDEXX Laboratories, Inc. — questions
- What is IDEXX Laboratories, Inc.'s market cap?
- $44.1B.
- What is IDEXX Laboratories, Inc.'s P/E ratio?
- 39.4 on trailing twelve-month earnings to 2026-06-30.
- What is IDEXX Laboratories, Inc.'s price-to-sales ratio?
- 9.7.
Every figure on this page comes from IDEXX Laboratories, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.